טוען...
Alemtuzumab for Multiple Sclerosis
Alemtuzumab is a humanised anti-CD52 monoclonal antibody approved for use in active, relapsing multiple sclerosis (MS). Administration results in a rapid depletion of circulating lymphocytes with a subsequent beneficial immune reconstitution. Early open-label experience and recent clinical trials ha...
שמור ב:
| הוצא לאור ב: | Curr Neurol Neurosci Rep |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4971037/ https://ncbi.nlm.nih.gov/pubmed/27485945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11910-016-0685-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|